Liquid Dutast 30mL 0.5mg/mL

Dutasteride (Dutast/Avodart) is a “5a-Reductase inhibitor” (5a-ri) that inhibits the conversion of testosterone to dihydrotestosterone (DHT) and has been proven extremely effective in treating and preventing DHT related hair loss. 5a-ri’s are used in the research and treatment of conditions that are exacerbated by DHT. A couple conditions that may be exacerbated by DHT are androgenic alopecia (Hair loss) and benign prostatic hyperplasia (BPH) also known as an "enlarged prostate". Dutast is also being researched for its possible use as a treatment for some neuropsychiatric disorders like schizophrenia and Tourette syndrome. Women who are pregnant should use great caution when handling Dutast during research studies. Why this is so is because it is absorbed through the skin very easily and has the potential risk of causing birth defects in pregnant women, gloves are a must here. Dutast has shown to be very effective in the treatment of MPB. This is an important area to continue research in because MPB is a very common condition that can have a very a big negative psychosocial impact for some sufferers. With this compound Dutast we now hold a way to further research and treat hair loss and may also lead to ways of full hair loss prevention, along with expanding our understanding of DHT and its effects in the body. We at CEM are proud to offer you the highest quality research compounds available for all your research needs! REF: 1) Androgens and hair loss .Alsantali A, Shapiro J.SourceDepartment of Dermatology and Skin Science, University of British Columbia, British Columbia, Canada http://www.ncbi.nlm.nih.gov/pubmed?term=dutasteride%20hair%20animal 2) Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasia.Chughtai B, Elterman DS, Lee R, Te AE, Kaplan SA. http://www.ncbi.nlm.nih.gov/pubmed/23024707 3) A multiscale, mechanism-driven, dynamic model for the effects of 5a-reductase inhibition on prostate maintenance.Zager MG, Barton HA. http://www.ncbi.nlm.nih.gov/pubmed/22970204 4) Promising therapies for treating and/or preventing androgenic alopecia.McElwee KJ, Shapiro JS. http://www.ncbi.nlm.nih.gov/pubmed/22735503 5) Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation.Moftah N, Moftah N, Abd-Elaziz G, Ahmed N, Hamed Y, Ghannam B, Ibrahim M. http://www.ncbi.nlm.nih.gov/pubmed/22486925 6) Effect of testosterone supplementation with and without a dual 5a-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial.Bhasin S, Travison TG, Storer TW, Lakshman K, Kaushik M, Mazer NA, Ngyuen AH, Davda MN, Jara H, Aakil A, Anderson S, Knapp PE, Hanka S, Mohammed N, Daou P, Miciek R, Ulloor J, Zhang A, Brooks B, Orwoll K, Hede-Brierley L, Eder R, Elmi A, Bhasin G, Collins L, Singh R, Basaria S. http://www.ncbi.nlm.nih.gov/pubmed/22396515 7) Development and characterization of dutasteride bearing liposomal systems for topical use.Sharma P, Jain D, Maithani M, Mishra SK, Khare P, Jain V, Singh R. http://www.ncbi.nlm.nih.gov/pubmed/21513483 8) Steroid 5a-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders.Paba S, Frau R, Godar SC, Devoto P, Marrosu F, Bortolato M. http://www.ncbi.nlm.nih.gov/pubmed/21361868